Skip to content
Screener

Incyte INCY Cumulative Cost Basis

Cumulative Cost Basis at other companies

Gilead Sciences logo
Gilead SciencesGILD
$8.71B+7.8%
Arcutis Biotherapeutics, Inc. logo
Arcutis Biotherapeutics, Inc.ARQT
$204.77M+73.5%
Arcus Biosciences logo
Arcus BiosciencesRCUS
$776M-16.3%
Agios Pharmaceuticals logo
Agios PharmaceuticalsAGIO
AbbVie logo
AbbVieABBV
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX

Other financials

Income statement

See full
Revenue$1.7B+37.7%
Gross profit$1.6B+38.0%
Operating income$697.9M+31.6%
Net income$585.6M+44.6%
EPS (diluted)$2.81+37.7%

Balance sheet

See full
Cash & equivalents$4.0B+104%
Total debt$38.3M-9.8%
Total equity$6.3B+52.1%
Total assets$7.9B+35.2%

Cash flow

See full
Operating cash flow$507.7M+1,035%
CapEx$1.6M-43.5%
Free cash flow$509.3M+1,069%

Valuation

See full
Market cap$24B+58.2%
Enterprise value$20.05B+51.3%
P/E14.9×-2.5×
P/S4.1×+0.8×

Profitability

See full
Gross margin92.6%-0.3pp
Operating margin30.6%+4.8pp
Net margin27.7%+8.7pp
FCF margin34%+12.3pp

Returns & leverage

See full
Return on equity30.7%+6.4pp
Debt / equity0.0×
Current ratio4.6×+1.7×

Where this comes from

Reported directly by Incyte in its filing.

Tagged under the XBRL concept us-gaap:PropertyPlantAndEquipmentGross.

The source filing: Incyte’s 10-Q, filed July 28, 2026.

Filed
Jul 28, 2026, 4:02 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0000879169-26-000056
Line itemJune 30,2026December 31,2025
Computer equipment167,619152,156
Land11,15611,273
Building and leasehold improvements606,693610,027
Operating lease right-of-use assets14,36519,596
Construction in progress26,72630,485
1,113,3831,105,951
Less accumulated depreciation and amortization(403,914)(375,066)
Property and equipment, net$709,469$730,885

Item 1. Financial Statements

FAQ

What is Incyte's cumulative cost basis?
Incyte (INCY) reported cumulative cost basis of $1.11B in Q2 2026.
How has Incyte's cumulative cost basis changed year-over-year?
Incyte's cumulative cost basis decreased by 2.8% year-over-year, from $1.14B to $1.11B.
What is the long-term trend for Incyte's cumulative cost basis?
Over 4 years (2021 to 2025), Incyte's cumulative cost basis has grown at a 5.3% compound annual growth rate (CAGR), from $899.64M to $1.11B.

Ask your AI about Incyte's cumulative cost basis.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude